Last reviewed · How we verify
Full dose of MVC-COV1901 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Full dose of MVC-COV1901 (Full dose of MVC-COV1901) — Medigen Vaccine Biologics Corp..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Full dose of MVC-COV1901 TARGET | Full dose of MVC-COV1901 | Medigen Vaccine Biologics Corp. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Full dose of MVC-COV1901 CI watch — RSS
- Full dose of MVC-COV1901 CI watch — Atom
- Full dose of MVC-COV1901 CI watch — JSON
- Full dose of MVC-COV1901 alone — RSS
Cite this brief
Drug Landscape (2026). Full dose of MVC-COV1901 — Competitive Intelligence Brief. https://druglandscape.com/ci/full-dose-of-mvc-cov1901. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab